Patents by Inventor Friedrich Lottspeich

Friedrich Lottspeich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230288402
    Abstract: The present invention relates to a method for identifying a pharmaceutically active compound that modulates the rpL35 (rpL35/rpL29)-dependent translation of at least one mRNA in a mammalian cell. The mRNA may comprise a premature termination codon (PTC), undergoes premature translation termination, causes programmed ?1 ribosomal frame shifting (?1PRF), or is a polycistronic mRNA. Furthermore a respective screening system, methods of treating or preventing a disease or condition, and compounds that modulate the rpL35 (rpL35/rpL29)-dependent translation, in particular atazanavir or derivatives thereof and artemisinin or artesunate or derivatives thereof are provided.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 14, 2023
    Inventors: HANNELORE BREITENBACH-KOLLER, JÖRG VON HAGEN, HELMUT HINTNER, FRIEDRICH LOTTSPEICH, HANS-WERNER MEWES, NORBERT MÜLLER, ANDREAS FRIEDRICH, KATHARINA ELSENSOHN, CLAUDIA MOSSHAMMER, MICHAEL WIESSNER, THOMAS KARL, JAN SCHERNTHANER, ADRIANA RATHNER
  • Patent number: 6602687
    Abstract: The present invention relates to nucleic acid sequences encoding ciliary neurotrophic factor (CNTF) and to the proteins, peptides, and derivatives produced therefrom. In various embodiments of the invention, the nucleic acid sequences, proteins, and peptides of the invention may be used in the treatment of a variety of neurological diseases and disorders, including Alzheimer's disease. In a specific embodiment of the invention, CNTF may be used to support the growth of spinal cord neurons, thereby providing a method of treating spinal cord damage caused by trauma infarction, infection, nutritional deficiency or toxic agents. The present invention also relates to a novel method for producing substantilly pure CNTF. The invention also relates to pharmaceutical compositions comprising effective amounts of CNTF gene products which may be used in the diagnosis and treatment of a variety of neurologial diseases and disorders.
    Type: Grant
    Filed: May 8, 1992
    Date of Patent: August 5, 2003
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Michael Sendtner, Kurt Stockli-Rippstein, Friedrich Lottspeich, Yoshihiro Arakawa, Patrick Desmond Carroll, Rudolf Georg Gotz, Georg W. Kreutzberg, Dan B. Lindholm, Piotr Masiakowski, Vivien Wong, Nancy Ip, Mark E. Furth, Nikos Panayotatos, Hans Thoenen
  • Patent number: 6451260
    Abstract: Described are novel methods for producing microporous elements and microporous elements obtainable by such methods. Provided are also microporous elements including solid microparticles, which preferably modify the adsorptive properties of the microporous element. Described are also microporous elements which are linked to a support and/or a retainer as well as methods for their production. Filter elements comprising the above-described microporous elements are also provided. Furthermore, kits, diagnostic and pharmaceutical compositions comprising the aforementioned microporous or filter elements are described. Furthermore, uses of the aforementioned microporous and filter elements in microfiltration, chromatography, adsorption/immobilization of organic and inorganic compounds as well as for the preparation and/or detection of such compounds are disclosed.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: September 17, 2002
    Assignee: Dyax Corp.
    Inventors: Andreas Düsterhöft, Thomas Manz, Ehrenfried Mehl, Friedrich Lottspeich
  • Patent number: 6448040
    Abstract: The present invention relates to nucleic acid molecules encoding hypusines mutants having the biological activity of an inhibitor of cellular proliferation. The present invention further relates to vectors comprising said nucleic acid molecules, to hosts transformed with said vectors, to methods of producing the polypeptide encoded by the nucleic acid molecule of the invention as well as to the polypeptide itself. In addition, the present invention relates to pharmaceutical and diagnostic compositions comprising one or more of the aforementioned compounds, the methods for synchronizing cell growth and to the use of the vector of the invention in gene therapy.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 10, 2002
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Craig Young, Friedrich Lottspeich, Adam Otasek
  • Patent number: 5453361
    Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying and isolating additional members of this gene family.
    Type: Grant
    Filed: January 21, 1992
    Date of Patent: September 26, 1995
    Assignees: Regeneron Pharmaceuticals, Inc., Max Plank Gesselschaft zur Forderung der Wissenschaften
    Inventors: George Yancopoulos, Yves-Alain Barde, Hans Thoenen, Friedrich Lottspeich, Joachim Leibrock
  • Patent number: 5438121
    Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. In a specific embodiment, BDNF may be used to promote the survival of substantia nigra dopaminergic neurons and basal forebrain cholinergic neurons, thereby providing a method for treating, respectively, Parkinson's disease and Alzheimer's disease. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen.
    Type: Grant
    Filed: April 25, 1991
    Date of Patent: August 1, 1995
    Assignees: Max-Planck-Gesellschaft zur Foderund der Wissenschaften e.V., Regeneron Pharmaceuticals, Inc.
    Inventors: Yves-Alain Barde, Joachim Leibrock, Friedrich Lottspeich, David Edgar, George Yancopoulos, Hans Thoenen
  • Patent number: 5229500
    Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. In a specific embodiment, BDNF may be used to promote the survival of substantia nigra dopaminergic neurons and basal forebrain cholinergic neurons, thereby providing a method for treating, respectively, Parkinson's disease and Alzheimer's disease. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: July 20, 1993
    Assignees: Regeneron Pharmaceuticals, Inc., Max Planck Gesellschaft
    Inventors: Yves-Alain Barde, Joachim Leibrock, Friedrich Lottspeich, David Edgar, George Yancopoulos, Hans Thoenen
  • Patent number: 5180820
    Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the ability to generate sufficient quantities of substantially pure BDNF for clinical use. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying an disolating additional members of this gene family.
    Type: Grant
    Filed: August 30, 1989
    Date of Patent: January 19, 1993
    Inventors: Yves-Alain Barde, Joachim Leibrock, Friedrich Lottspeich, George Yancopoulos, Hans Thoenen
  • Patent number: 4681871
    Abstract: Pharmacologically active peptides with opiate-like activity are provided having stability to proteases. The products can be obtained by enzymatic digestion of casein.The active peptides have the grouping Tyr-Pro-A where Tyr is tyrosine, Pro is proline and A is any amino acid group.
    Type: Grant
    Filed: January 22, 1981
    Date of Patent: July 21, 1987
    Inventors: Hansjorg Teschemacher, Victor Brantl, Agnes Henschen, Friedrich Lottspeich
  • Patent number: 4555403
    Abstract: Peptides of the formula Tyr.sup.1 -X-A-Pro-B-Pro-C-Pro-D, in which Tyr.sup.1 is equal to the amino acid tyrosine and Pro is equal to the amino acid proline; A, B, C, D is any desired amino acid in the L-form and X any amino acid in the D-form, except D-proline, D-alanine, D-threonine and D-valine, preferably D-serine, D-arginine or D-methionine; they act opiate-like and may be used as medicaments and animal medicaments.
    Type: Grant
    Filed: June 24, 1983
    Date of Patent: November 26, 1985
    Inventors: Victor Brantl, Hansjorg Teschemacher, Agnes Henschen, Friedrich Lottspeich
  • Patent number: 4390527
    Abstract: Peptides of the formula Tyr.sup.1 -X-A-Pro-B-Pro-C . . . . . . . . , in which Tyr.sup.1 is equal to the amino acid tyrosine and Pro is equal to the amino acid proline; A, B, C is any desired amino acid in the L-form and X any amino acid in the D-form; they act opiate-like and may be used as medicaments and animal medicaments.
    Type: Grant
    Filed: April 29, 1981
    Date of Patent: June 28, 1983
    Inventors: Victor Brantl, Agnes Henschen, Hansjorg Teschemacher, Friedrich Lottspeich